Clinical effect of different doses of alteplase in the treatment of patients with acute mild ischemic stroke
Objective To investigate the efficacy and safety of intravenous thrombolysis with different doses of recombinant tissue plasminogen activator(rt-PA)in patients with acute mild ischemic stroke(MIS).Methods Forty-four patients with acute MIS who received low-dose rt-PA(0.6 mg/kg,total dose≤60 mg)intravenous thrombolysis in Liuzhou People's Hospital from October 2018 to December 2021 were retrospectively included as low-dose group,and 62 patients with acute MIS who received standard-dose rt-PA(0.9 mg/kg,total dose≤90 mg)intravenous thrombolysis at the same time were included as standard-dose group.The therapeutic effects of the two groups were compared.Results There was no significant difference in clinical data between the two groups(P>0.05).There was no significant difference in the proportion of good prognosis[Modified Rankin Scale(mRS)score 0-2]between the two groups at 7 and 90 d after thrombolysis(P>0.05).There was no significant difference in the incidence of intracranial hemorrhage after thrombolysis between the two groups(P=0.397).Conclusion Intravenous thrombolysis therapy with rt-PA is safe and effective in patients with acute MIS,but low-dose thrombolysis therapy may be better.
NETL
NSTL
万方数据
